

7 Literatur

1. Ackermann JJH, Grove TH, Wong GG, et al: Mapping of metabolites in whole animals by ³¹P NMR using surface coils. *Nature* 283:167-170, 1980.
2. Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. *Neurology* 42:733, 1992.
3. Alger JR, Frank JA, Bizzi A, et al. Metabolism of human gliomas: assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET. *Radiology* 177:633-641, 1990.
4. Beal MF, Brouillet E, Jenkins BG, et al. Neurochemical and histologic characterization of excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. *J Neurosci* 13:4181-4191, 1993.
5. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? *Ann Neurol* 31:119-130, 1992.
6. Beal MF. Energetics in the pathogenesis of neurodegenerative diseases. *Trends Neurosci.* 23:298-304, 2000.
7. Bertolino A, Callicott JH, Elman I, et al. Regionally Specific Neuronal Pathology in Untreated Patients with Schizophrenia: A Proton Magnetic Resonance Spectroscopic Imaging Study. *Biol Psychiatry* 43:641-648, 1998.
8. Bloch F, Hansen WW, Packard M: The nuclear induction experiment. *Phys Rev* 70:437-445, 1946.
9. Bloms-Funke P, Loscher W. The anticonvulsant gabapentin decreases firing rates of substantia nigra pars reticulata neurons. *Eur J Pharmacol* 316(2-3):211-8 ; Dec 5 1996.
10. Brouillet E, Hantraye P, Ferrante RJ, et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. *Proc Natl Acad Sci USA* 92:7105-7109, 1995.
11. Bruhn H, Frahm J, Gyngell ML, et al. Cerebral metabolism in man after acute stroke: New observations using localized proton NMR spectroscopy. *Magn Reson Med* 9:126-131, 1989.

12. Bruhn H, Frahm J, Gyngell ML, et al. Localized proton spectroscopy of tumors in vivo: Patients with primary and secondary cerebral tumors. Abstracts of the Society for Magnetic Resonance in Medicine. San Francisco p. 253, 1988.
13. Bruhn H, Frahm J, Gyngell ML, et al. Noninvasive differentiation of tumors with use of localized ^1H -MR spectroscopy in vivo: Initial experience in patients with cerebral tumors. *Radiology* 172:541-548, 1989.
14. Callicott JH, Egan MF, Bertolino A, et al. Hippocampal N-Acetyl Aspartate in Unaffected Siblings of Patients with Schizophrenia: A Possible Intermediate Neurobiological Phenotype. *Biol Psychiatry* 44:941-950, 1998.
15. Chang L, Ernst T, Leonido-Yee M, et al. Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia. *Neurology*, 53:782-789, 1999.
16. Chantal S, Labelle M, Bouchard RW, Braun CM, Boulanger Y. Correlation of regional proton magnetic resonance spectroscopic metabolic changes with cognitive deficits in mild Alzheimer disease. *Arch Neurol*, Jun;59(6):955-62, 2002.
17. Chen JC, Hardy PA, Clauberg M, et al. T2 values in the human brain: comparison with quantitative assays of iron and ferritin. *Radiology* 173:521-526, 1989.
18. Cheramy A, Desce JM, Godeheu G, Glowinski J. Presynaptic control of dopamine synthesis and release by excitatory amino acids in rat striatal synaptosomes. *Neurochem Int* 25:145-154, 1994.
19. Choe B, Desce JM, Godeheu G, Glowinski J. Postmortem Metabolic and Morphologic Alterations of the Dog Brain Thalamus with Use of In Vivo ^1H Magnetic Resonance Spectroscopy and Electron Microscopy. *Neurochem Int* 25:145-154, 1994.
20. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. *Science* 262:689-700, 1993.
21. Damadian R, Goldsmith M, Minkoff L: Fonar image of the live human body. *Physiol Chem Phys Med NMR* 9:97, 1977.
22. Damadian R, Minkoff L, Goldsmith M, et al. Field focusing NMR (FONAR): Visualization of a tumor in a live animal. *Science* 194:1430-1432, 1976.

23. De Stefano N, Dotti MT, Mortilla M, Federico A. Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis. *Brain*, Jan;124(Pt 1):121-31, 2001.
24. Edelman RR, Hesselink JR, et al. Clinical Magnetic Resonance Imaging. W.B. Saunders Company, 1990.
25. Ernst RR, Anderson WA. *Rev Sci Instrum* 37:93, 1966.
26. Evert, BO, Wullner U, Klockgether T. Cell death in polyglutamine diseases. *Cell Tissue Res* 301:189-204, 2000.
27. Fenstermacher MJ, Narayana PA. Serial proton magnetic resonance spectroscopy of ischemic brain injury in humans. *Invest Radiol* 9:1034-1039, 1990.
28. Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. *J Neurosci*, Mar 1;22(5):1592-9, 2002.
29. Ferrante RJ, Andreassen OA, Jenkins BG, et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. *J Neurosci*, Jun 15;20(12):4389-97, 2000.
30. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. *Journal of Psychiatric Research* 12:189-198, 1975.
31. Frahm J, Merboldt KD, Hänicke W, et al. Stimulated echo imaging. *J Magn Reson* 64:81-93, 1985.
32. Frahm J, Merboldt KD, Hänicke W. Localized Proton Spectroscopy Using Stimulated Echoes. *J Magn Res* 72: 502-508, 1987.
33. Gerthsen C, Vogel H. Physik 17. Auflage. Springer Verlag, 1993.
34. Gervais FG, Singaraja R, Xanthoudakis S et al. Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hipp1. *Nature Cell Biol*, 14 January 2002.
35. Goldberg YP, McMurray CT, Zeisler J, et al. Increased instability of intermediate alleles in families with sporadic Huntington disease compared to similar sized intermediate alleles in the general population. *Hum Mol Genet* 4:1911-1918, 1995.

36. Gordon RE, Hanley PE, Shaw D, et al. Localization of metabolites in animals using ^{31}P topical magnetic resonance. *Nature* 287:367-368, 1980.
37. Gramsbergen JB, Veenma-Van der Duin L, Venema K, Korf J. Cerebral cation shifts and amino acids in Huntington's disease. *Arch Neurol* 43: 1276-81, 1986.
38. Haase A, Frahm J, Matthaei D, et al. MR Imaging Using Stimulated Echoes (STEAM). *Radiology* 160: 787-790, 1986.
39. Harms L, Meierkord H, Timm G, Pfeiffer L, Ludolph AC. Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study. *J Neurol Neurosurg Psychiatry* 62:27-30, 1997.
40. Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. *Mov Disord* 11:136-42, 1996.
41. Jayasundar R, Sahani AK, Gaikwad S, Singh S, Behari M. Proton MR spectroscopy of basal ganglia in Wilson's disease: case report and review of literature. *Magn Reson Imaging*, Jan;20(1):131-5, 2002.
42. Jenkins B, Koroshetz W, Beal MF, Rosen B. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized proton spectroscopy. *Neurology* 43:2689-2695, 1993.
43. Jenkins BG, Klivenyi P, Kustermann E, Andreassen OA, Ferrante RJ, Rosen BR, Beal MF. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. *J Neurochem*, May;74(5):2108-19, 2000.
44. Jenkins BG, Rosas HD, Chen Y-CI, Makabe T, Koroshetz WJ, et al. ^1H NMR spectroscopy studies of Huntington's disease, Correlations with CAG repeat numbers. *Neurology* 50:1357-1365, 1998.
45. Jenkins BG, Storey E, Beal MF, Rosen BR. Chemical shift imaging of focal neurochemical lesions in rat brains. *Book of abstracts, Soc Magn Res Med, 10th annual meeting, San Francisco, CA* p437, 1991.
46. Koeppen AH. The hereditary ataxias. *J Neuropathol Exp Neurol* 57:531-543, 1998.
47. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. Energy metabolism defects in Huntington's disease and effects of coenzyme Q¹⁰. *Ann Neurol* 41:160-165, 1997.

48. Kuhl DE, Phelps ME, Markham CH, Metter EJ, Riege WH, Winter J. Cerebral metabolism and atrophy in Huntington's disease determined by ¹⁸FDG and computed tomographic scan. *Ann Neurol* 12:425-434, 1982.
49. Kuwert T, Lange HW, Langen K-J, Jerzog H, Aulich A, Feinendegen LE. Cortical and subcortical glucose consumption measured using PET in patients with Huntington's disease. *Brain* 113:1405-1423, 1990.
50. Laccone F, Engel U, Holinski-Feder E, et al. DNA analysis of Huntington's disease. Five years of experience in Germany, Austria, and Switzerland. *Neurology* 53:801-806, 1999.
51. Lauterbur PC. *Nature* 242:190, 1973.
52. Leenders KL, Fracowiak RSJ, Quinn N, Marsden CD. Brain energy metabolism and dopaminergic function in Huntington's disease measured using positron emission tomography. *Mov Disord* 1:69-77, 1986.
53. Liu H, Hall WA, et al. An Efficient Chemical Shift Imaging Scheme for Magnetic Resonance-Guided Neurosurgery. *J Magn Reson Imaging*, 14:1-7, 2001.
54. Ludolph A, Seelig M, Ludolph A, et al. 3-Nitropropionic acid: exogenous animal neurotoxin and possible human striatal toxin. *Can J Neurol Sci* 18:492-498, 1992.
55. Mangiarini L, Sathysivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. *Cell* 87:493-506, 1996
56. Mariappan SVS, Subramanian S, Chandrakumar N, et al. Proton relaxation times in cancer diagnosis. *Magn Reson Med* 8:119-128, 1988.
57. Martin WRW, Clark C, Ammann W, Stoessl AJ, Shtybel W, Hayden MR. Cortical glucose metabolism in Huntington's disease. *Neurology* 42:223-229, 1992.
58. Martin WRW, Hanstock C, Hodder J, Allen PS. Brain energy metabolism in Huntington's disease measured with in vivo proton magnetic resonance spectroscopy. *Ann Neurol* 40:538, 1996. *Abstract*
59. Mattson, MP. Apoptosis in neurodegenerative disorders. *Nature Rev. Mol. Cell Biol.* 1:120-129, 2000.
60. McNeil SM, Novelletto A, Srinidhi J, et al. Reduced penetrance of the Huntington's disease mutation. *Hum Mol Genet* 6:775-779, 1997.

61. Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative diseases. *Trends Physiol Sci* 11:379-387, 1990.
62. Miller BL, Moats RA, Shonk TK, Ernst T, Wooley S, Ross BD. Alzheimer disease: depiction of increase cerebral myo-inositol with proton MR spectroscopy. *Radiology* 187:433-437, 1993.
63. Mukonoweshuro W, Wilkinson ID, Griffiths PD. Proton MR spectroscopy of cortical tubers in adults with tuberous sclerosis complex. *AJNR Am J Neuroradiol*, Nov-Dec;22(10):1920-5, 2001.
64. Myers RH, Sax DS, Koroshetz WJ, et al. Factors associated with slow progression in Huntington's disease. *Arch Neurol* 48:800-804, 1991.
65. Novelli A, Reilly JA, Lysko PG, Henneberry RC. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. *Brain Res* 451:205-212, 1988.
66. O'Brien CF, Miller C, Goldblatt D, et al. Extraneural metabolism in early Huntington's disease. *Ann Neurol* 28:300-301, 1990.
67. Olanow CW. A radical hypothesis for neuronal degeneration. *Trends Neurosci* 16:439-443, 1993
68. Petroff OAC, Rothman DL, Behar KL, et al. The Effect of Gabapentin on Brain Gamma-aminobutyric Acid in Patients with Epilepsy. *Ann Neurol* 39:95-99, 1996.
69. Proctor WG, Yu FC: The dependence of a nuclear magnetic resonance frequency upon chemical compound. *Phys Rev* 77:717 (Letters to the editor), 1950.
70. Provencher SW. Automatic quantitation of localized in vivo ¹H spectra with LCModel. *NMR Biomed* Jun;14(4):260-4, 2001.
71. Provencher SW. Estimation of Metabolite Concentrations from Localized in Vivo Proton NMR Spectra. *Magn Res Med* 30(6):672-9, Dec 1993.
72. Purcell EM, Torey HC, Pound RV: Resonance absorption by nuclear magnetic moments in a solid. *Phys Rev* 69:37-38 (Letters to the editor), 1946.
73. Rabi II, Millman S, Kusch P, et al: The molecular beam resonance method for measuring nuclear magnetic moments. *Phys Rev* 55:526, 1939.
74. Rosas HD, Goodman J, Chen YI, Jenkins BG, Kennedy DN, Makris N, Patti M, Seidman LJ, Beal MF, Koroshetz WJ. Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. *Neurology*, Sep 25;57(6):1025-8, 2001.

75. Rothstein JD, Kuncl RW. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. *J Neurochem* 65(2):643-51, 1995.
76. Sarchielli P, Pelliccioli GP, Tarducci R, Chiarini P et al. Magnetic resonance imaging and ¹H-magnetic resonance spectroscopy in amyotrophic lateral sclerosis. *Neuroradiology*, Mar;43(3):189-97, 2001.
77. Schlemmer HP, Bachert P, et al. Proton MR Spectroscopic Evaluation of Suspicious Brain Lesions After Stereotactic Radiotherapy. *AJNR Am J Neuroradiol* 22:1316–1324, 2001.
78. Schulz JB, Beal MF. Mitochondrial dysfunction in movement disorders. *Curr Opin Neurol* 7:333-339, 1994.
79. Shoulson I. Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. *Neurology* 31:1333-5, 1981.
80. Shukla-Dave A, Gupta RK, Roy R, et al. Prospective evaluation of in vivo proton MR spectroscopy in differentiation of similar appearing intracranial cystic lesions. *Magnetic Resonance Imaging*, 19: 103-110, 2001.
81. Shulman K, Shedletsky R, Silver I. The challenge of time: clock drawing and cognitive function in the elderly. *International Journal of Geriatric Psychiatry* 1: 135-140, 1986.
82. Strauss WL, Tsuruda JS, Richards TL. Partial volume effects in volume-localized phased-array proton spectroscopy of the temporal lobe. *Journal of Magnetic Resonance Imaging* 5(4):433-436, 1995.
83. Strong TV, Tagle DA, Valdes JM, et al. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissue. *Nature Genet* 5:259-265, 1993.
84. Suwanwela N, Phanuphak P, Phanthumchinda K, et al. Magnetic resonance spectroscopy of the brain in neurologically asymptomatic HIV-infected patients. *Magnetic Resonance Imaging* 18:859–865, 2000.
85. Taylor-Robinson SD, Weeks RA, Bryant DJ, et al. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory. *Mov Disord* 11(2):167-73, 1996.

86. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. *Cell* 72:971-983, 1993
87. Thomas MA, Binesh N, et al. Volume-Localized Two-Dimensional Correlated Magnetic Resonance Spectroscopy of Human Breast Cancer. *J Magn Res Imaging*, 14:181-186, 2001.
88. Tkac I, Andersen P, et al. In Vivo ¹H NMR Spectroscopy of the Human Brain at 7 T. *Magnetic Resonance in Medicine*, 46:451-456, 2001.
89. Tzika AA, Cheng LL, Goumnerova L, Madsen JR, et al. Biochemical characterization of pediatric brain tumors by using in vivo and ex vivo magnetic resonance spectroscopy. *J Neurosurg*, Jun;96(6):1023-31, 2002.
90. Urejnak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance unambiguously identifies neural cell types: *J Neurosci* 13:981-989, 1993.
91. Venkatesh SK, Gupta RK, et al. Spectroscopic Increase in Choline Signal Is a Nonspecific Marker for Differentiation of Infective/Inflammatory From Neoplastic Lesions of the Brain. *J Magn Res Imaging*, 14:8-15, 2001.
92. Vigneron D, Bollen A, McDermott M, et al. Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors. *Magnetic Resonance Imaging*, 19:89-101, 2001.
93. Vigneron DB, Barkovich AJ, Noworolski SM, et al. Three-dimensional Proton MR Spectroscopic Imaging of Premature and Term Neonates. *AJNR Am J Neuroradiol*, 22:1424-1433, 2001.
94. Wallace DW. Mitochondrial genetics: a paradigm for aging and degenerative diseases? *Science* 256:628-632, 1992.
95. Yeung DK, Cheung HS, Tse GMK. Human Breast Lesions: Characterization with Contrast-enhanced in Vivo Proton MR Spectroscopy-Initial Results. *Radiology*, 220:40-46, 2001.
96. Young AB, Penney JB, Starosta-Rubenstein S, et al. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurologic features and functional decline. *Ann Neurol* 20:296-303, 1986.
97. Saunders DE. MR spectroscopy in stroke. *Br Med Bull*, 56(2):334-45, 2000.

98. Law M, Cha S, Knopp EA, Johnson G. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. *Radiology*, 222(3):715-21, 2002.